The function of osteoclasts is to resorb bone, and they represent the major cell type responsible for this critical step in homeostatic bone remodeling and in pathological bone loss disorders[@b1][@b2]. Recent years have seen remarkable advances in the understanding of the signaling pathways required for osteoclast formation and activation, and of how these processes are regulated by the essential osteoclastogenic cytokines Receptor activator of nuclear factor kappa-B ligand (RANKL) and Macrophage colony-stimulating factor (M-CSF)[@b3][@b4][@b5]. RANKL and M-CSF are necessary and sufficient for the in vitro generation from myeloid precursor cells of multinucleated cells that bear the hallmarks of osteoclasts. The ability to generate osteoclast-like cells *in vitro* with high efficiency has been instrumental in identifying at a molecular level numerous key factors involved in this process. However, these studies have almost without exception been limited to cells differentiated on tissue culture plastic or glass surfaces, and have therefore failed to address the critical role played by bone substrate in osteoclast differentiation, polarization, and activation[@b6][@b7][@b8][@b9][@b10][@b11]. Since fully functional osteoclasts exist exclusively upon bone surfaces in vivo, the paucity of information regarding how bone substrate regulates these cells represents a significant and important gap in our knowledge of osteoclast biology.

Integrin beta 3 (itgb3) is a critical mediator of the interaction of differentiating osteoclasts with bone substrate[@b12][@b13]. Itgb3 is highly induced in differentiating and mature osteoclasts, and forms a complex with integrin alpha v on the surface of osteoclasts that binds to extracellular matrix components present in bone and thus plays an important role in osteoclast-bone interactions. Mice lacking itgb3 generate osteoclasts that are unable to properly polarize upon bone substrates, and thus exhibit a defect in bone resorption, accentuating the critical role of itgb3 mediated adhesion to bone in osteoclast differentiation and activation[@b12]. A critical role for itgb3 has also been demonstrated in mouse models of ovariectomy-induced osteoporosis[@b14] and cancer metastasis to bone[@b15].

In this study we have provided the first comprehensive gene expression profiling of mouse bone marrow macrophage (BMM)-derived osteoclasts on bone and hydroxyapatite (HA) substrates. Using time course analysis of osteoclasts generated on plastic, HA and bone, we have identified a unique cluster of osteoclast genes specifically up-regulated by bone substrate. Further, we have compared the induction of these genes in wild type and itgb3 knockout (*Itgb3* −/−) cells differentiated on bone to delineate the role of itgb3 in activation of bone-dependent osteoclast genetic programs. These analyses identified the pathway responsible for synthesis, transport and signaling by the lipid mediator sphingosine-1-phosphate (S-1-P) as a prototypical member of the bone- and itgb3-regulated genes and additional studies confirmed the critical role of this pathway in regulating the differentiation and activation of osteoclasts. Furthermore, we have demonstrated that bone substrate regulates the switch from cell cycle progression to differentiation and activation at late stages of osteoclastogenesis.

Results
=======

Expression profiling of mouse osteoclasts differentiated on bone related substrates
-----------------------------------------------------------------------------------

In order to determine the role of bone matrix in osteoclast formation and function, we differentiated mouse BMMs to osteoclasts on authentic devitalized mouse bone, or on the non-bone substrates HA or tissue culture plastic. After 5 days of culture with RANKL, osteoclasts on mouse calvarial bone discs displayed actin rings characteristic of polarized and actively resorbing osteoclasts while osteoclast-like cells on plastic displayed characteristic podosome bands ([Fig. 1a and 1b](#f1){ref-type="fig"} respectively)[@b16].

As detailed in *Methods*, quadruplicate cultures prepared from individual animals were processed for RNA extraction at early (day 1), intermediate (day 3) and terminal (day 5) stages of RANKL-induced osteoclastogenesis. BMMs were cultured for equivalent times on mouse bone, HA and tissue culture plastic, in the presence of M-CSF, but not RANKL as a control.

Following confirmation of RNA quality by Biacore analysis and analysis of results from hybridization to test chips, genome-wide expression profiles were determined on Affymetrix Gene Chips (Mouse Genome 430 2.0) for each of the 4 replicates with and without RANKL, on each substrate and over 3 time points. Hierarchal cluster analysis identified gene clusters specifically regulated by RANKL (independent of substrate) and by substrate-dependence ([Fig. 1c](#f1){ref-type="fig"}). In accordance with previous studies, this analysis revealed that RANKL, independent of substrate, induced expression of subsets of genes with known involvement in osteoclast biology and function, including: TRAP, cathepsin-k, calcitonin receptor, itgb3, OSCAR, and NFATc1. The RANKL-induced expression profiles transitioned substantially during the time-course of the analysis, as the macrophage precursors differentiated through the stages of pre-osteoclast, committed osteoclast precursors, and differentiated, bone-resorbing osteoclast. As delineated in [Fig. 1d](#f1){ref-type="fig"}, the number of RANKL regulated genes increased substantially between days 1--3, when pre-osteoclasts are differentiating into immature osteoclasts, and increased more moderately during the later stages of differentiation of fully mature osteoclasts (days 3--5).

Substrate induction of RANKL induced genes
------------------------------------------

Notably, we also observed that the well-established pattern of RANKL-induced osteoclast gene expression could be significantly reprogrammed by the nature of the growth substrate. At each time point, a subset of the RANKL-induced genes was further regulated by the presence of bone. Osteoclasts differentiated on HA substrate (not shown) tended towards an expression profile intermediate to those seen on plastic and bone. As shown in [Fig. 1d](#f1){ref-type="fig"}, the numbers of RANKL-induced genes that were super-regulated both positively and negatively by bone substrate, were considerably higher on day 5, when the osteoclasts are undergoing terminal differentiation and activation, than at earlier time points. Interestingly, there was little overlap in the gene sets super-regulated by bone at the different time-points ([Fig. 1e](#f1){ref-type="fig"}), suggesting that the bone regulated expression program is linear and highly dynamic, and dependent upon the differentiation state of the cell.

Specific subsets of bone-regulated osteoclast genes are dependent upon itgb3, whereas other genes are itgb3-independent
-----------------------------------------------------------------------------------------------------------------------

Since itgb3 has been shown to play a critical role in regulating the morphological and functional activity of osteoclasts[@b12], we next assessed the contribution of itgb3 signaling to the identified bone-dependent gene expression profile. Consistent with its role in interaction with bone substrate, expression of itgb3 was induced by RANKL, and super-induced by bone substrate during late stages of osteoclast differentiation ([Fig. 2a](#f2){ref-type="fig"}). To directly address the role of itgb3 in bone regulated osteoclastogenesis, BMMs from three individual wild-type and three individual Itgb3 knockout mice (*Itgb3* −/−) were isolated and subjected to osteoclastogenesis (in the presence of M-CSF and RANKL) on tissue culture plastic and devitalized mouse calvarial bone slices, as described above. Actin ring staining by Rhodamine Phalloidin confirmed that although *itgb3* −/− osteoclasts retain the ability to attach to the bone surface, they fail to form actin rings, consistent with the defective resorption activity of osteoclasts lacking itgb3 ([Fig. 2b](#f2){ref-type="fig"})[@b12][@b17][@b18][@b19][@b20][@b21][@b22].

Consistent with the pre-eminent role of itgb3 in osteoclastogenesis, microarray analysis and hierarchical clustering ([Fig. 2c](#f2){ref-type="fig"}) revealed that absence of this integrin resulted in significant changes in the pattern of gene expression during RANKL-induced differentiation of BMMs. Significantly, cluster analysis identified not only sets of bone-regulated genes that were dependent upon the presence of itgb3, but a novel cluster of genes whose induction by bone substrate was unaffected or enhanced by the absence of itgb3. The identification of bone-regulated, itgb3-independent genes is notable since it implies the existence of multiple bone-derived signaling pathways for regulation of gene expression in differentiating osteoclasts.

Independently qPCR analysis was utilized to confirm the ability of bone to up-regulate specific osteoclast genes in either an itgb3-independent (e.g. AnxA8) or itgb3-dependent (e.g. UCHL1 and FKBP9) manner ([Table 1](#t1){ref-type="table"}).

Taken together, the results from expression profiling show that multiple mechanisms including cytokine signaling (RANKL), integrin-based attachment to substrate (itgb3) and the nature of the substrate itself (bone) drive gene expression and cell differentiation of osteoclasts. Moreover, these different regulators of osteoclast differentiation operate in overlapping fashion to coordinate the complex events that constitute osteoclast formation and activation.

Pathway analysis and functional classification
----------------------------------------------

Several approaches were taken towards identification of the signaling pathways coordinately regulated by bone substrate and/or itgb3 during RANKL-induced osteoclastogenesis. Ingenuity Pathway Analysis (IPA) identified several bone regulated functional categories, including regulation of cell survival and proliferation ([Table 2](#t2){ref-type="table"}). Gene Set Enrichment Analysis (GSEA) was further used as a means to look for pathways that were differentially regulated by these stimuli. This confirmed that bone substrate profoundly influences osteoclast proliferation and differentiation, as highlighted by a bone substrate-induced repression of expression of genes associated with cell cycle progression and cell division ([Fig. 3a](#f3){ref-type="fig"}).

As highlighted for representative genes cdc7 and cyclin b1 ([Fig. 3b](#f3){ref-type="fig"}), genes within this pathway show a modest decrease between days 3--5 on plastic, but a much more prominent loss of expression during the same period of culture on bone. The repression of cell cycle genes in osteoclast differentiation on bone indicates the induction of a transcriptional program that arrests osteoclast proliferation during the late stages of osteoclast differentiation. Absence of itgb3 had a remarkably similar impact upon this pathway as absence of bone (i.e. growth on plastic), with numerous genes associated with cell cycle progression being elevated in day 5 osteoclasts in the absence of itgb3 ([Fig. 3a](#f3){ref-type="fig"}). This strongly reaffirms the importance of itgb3 for osteoclast development, and indicates that the bone substrate mediated decline in cell cycle progression is a highly itgb3-dependent process. Interestingly, macrophages cultured in the absence of RANKL also show a decrease in expression of cdc7 and Cyclin B1 between 3 and 5 days in culture (−RL in [Fig. 3b](#f3){ref-type="fig"}) as the cells reach confluency. However, unlike in osteoclasts, this effect is not modulated by bone substrate, suggesting that the bone substrate-mediated switch from proliferation to activation is specific for RANKL-induced osteoclasts and not a common feature of myeloid cells.

Regulation of the S-1-P pathway during osteoclastogenesis on bone substrate
---------------------------------------------------------------------------

GSEA analysis identified several additional pathways regulated by bone and itgb3. Prominent among these was the S-1-P pathway (termed the EDG1 pathway in this analysis, with EDG1 being a cell surface receptor for S-1-P), which includes the protein mediators involved in the generation, transport and signaling of S-1-P. Based upon this observation, and the fact that a number of reports have suggested an important role for S-1-P and EDG signaling in osteoclast biology[@b23][@b24][@b25][@b26][@b27][@b28], we investigated this pathway in greater detail.

GSEA analysis revealed that the S-1-P pathway was significantly regulated independently by RANKL, bone substrate and itgb3 ([Fig. 4a](#f4){ref-type="fig"}). Analysis of the microarray data for probes for sphingosine kinase 1 (SphK1), a key regulator of S-1-P synthesis, revealed robust induction by RANKL during osteoclast differentiation (day 3--5), with super-induction by bone substrate most prominent at later stages of terminal differentiation and activation (day 5) ([Fig. 4b](#f4){ref-type="fig"}), whereas the related kinase SphK2 was not regulated by RANKL or bone substrate (not shown). Interestingly, Spns2, a more recently identified S-1-P transporter[@b29], is regulated in a manner very similar to that of SphK1, suggesting coordinated regulation of S-1-P synthesis and transport ([Fig. 4b](#f4){ref-type="fig"}). Pathway analysis revealed that key components of the S-1-P pathway are regulated by each of the critical determinants of osteoclast formation and activation; RANKL, bone and itgb3 ([Fig. 4c](#f4){ref-type="fig"}), suggesting that this pathway integrates signals emanating from RANKL signaling, itgb3 engagement, and attachment to bone. Finally, immunohistochemical analysis of bone erosions in tissue from a patient with rheumatoid arthritis (RA) revealed strong and specific SphK1 expression within osteoclasts indicating that the initial observation of Sphk1 up-regulation in bone adherent osteoclasts using mouse cells in culture is directly translated to human osteoclasts associated with inflammatory bone loss ([Fig. 4d](#f4){ref-type="fig"}). Additionally, attachment of these osteoclasts to the bone surface further supports the Sphk1 kinase as a target of regulation by bone.

SphK1 inhibitors negatively regulate osteoclastogenesis
-------------------------------------------------------

The preceding results show that the S-1-P pathway is up-regulated in response to RANKL and also to bone substrate, and that this up-regulation is dependent, at least in part, by itgb3-mediated interactions between the differentiating osteoclasts and the bone substrate. To address the role of EDG pathway induction in osteoclastogenesis, SphK inhibitors N′,N′ Dimethylsphingosine (N′,N′-DMS) and the SphK1-selective Compound 54[@b30] were evaluated for effects on *in vitro* osteoclast formation from human and mouse precursors.

To assess the potential effects of SphK1 inhibition on osteoclastogenesis, mouse BMM were incubated with M-CSF and RANKL in the presence or absence of different doses of the SphK inhibitors. When present throughout the 5 days of culture, both inhibitors dose-dependently inhibited generation of tartrate resistant acid phosphatase (TRAP)-positive multinuclear osteoclasts ([Fig. 5a](#f5){ref-type="fig"}). As expected, loss of formation of TRAP-positive osteoclasts was reflected in an inhibition in the formation of resorptive pits when the osteoclasts were generated on bone slices ([Fig. 5b](#f5){ref-type="fig"}). In addition, induction of expression of osteoclast specific genes was also dose-dependently inhibited by both of the inhibitors, as illustrated for cathepsin K ([Fig. 5c](#f5){ref-type="fig"}). To address at which stage of osteoclastogenesis SphK1 activity is required, osteoclastogenesis assays were performed in which inhibitors were only present during either the first 3 days of culture, or the final 2 days. Interestingly, inhibition of osteoclastogenesis was seen in both cases, albeit to a lesser degree than when inhibitors were present throughout, suggesting that SphK1 inhibition can block osteoclast formation at multiple stages of differentiation ([Fig. 5a](#f5){ref-type="fig"}). Finally, the effects of SphK1 inhibitors on human monocyte-derived osteoclastogenesis were evaluated. As seen for murine cells, these validated inhibitors showed a dose dependent inhibition of RANKL-induced formation of TRAP-positive osteoclasts ([Fig. 5d](#f5){ref-type="fig"}) as well as inhibition of osteoclast gene expression (data not shown). These results show that SphK1 inhibition potently blocks induction of osteoclast genes and formation of multinucleated osteoclasts in both mouse and human *in vitro* systems.

Taken together, these results show that genes of the S-1-P pathway are not only co-coordinately regulated by RANKL signaling, itgb3-mediated attachment, and bone substrate, but also that this pathway plays a critical role in osteoclastogenesis and activation. In turn, this validates the profiling studies on the role of bone and itgb3 for the identification of important pathways regulating osteoclastogenesis on bone substrates.

Discussion
==========

By definition, functional osteoclasts exist only on bone surfaces, both in the context of normal bone homeostasis and in inflammatory osteolysis, since it is only when associated with bone that these cells perform their unique and required cellular activity, namely bone resorption. This observation stresses the importance of considering the cell culture substrate when analyzing the cellular and molecular mechanisms regulating osteoclast differentiation and activation *in vitro*. To address this need, we have recently demonstrated that differentiation on bone substrates can profoundly influence osteoclast differentiation[@b8][@b9][@b11]. A wealth of valuable information on the regulation of osteoclastogenesis has been derived from studies of osteoclast cells on tissue culture plastic induced by the pro-osteoclastogenic cytokines M-CSF and RANKL[@b6][@b7][@b31][@b32][@b33][@b34][@b35][@b36][@b37]. However, little attention has been paid to this process in the context of bone substrate, leaving the details of bone regulation of osteoclast gene expression largely unexplored. This remains an important gap in our knowledge of osteoclast biology, particularly so because bone regulated osteoclast products may represent novel and specific candidate molecules for therapeutic targeting of the osteoclast. In this paper, we have addressed this knowledge gap by providing the first comprehensive characterization on the role of bone substrates on gene expression during osteoclast differentiation and activation.

Microarray analysis, coupled to qPCR validation and pathway analysis revealed a number of gene clusters specifically modified by bone substrate. Focusing on bone regulation of gene sets induced by RANKL identified coordinated repression by bone during the later stages of osteoclastogenesis of genes involved in cell cycle progression and cell division. This would be consistent with a transition during late osteoclastogenesis from expansion and fusion of the precursor pool towards polarization and initiation of bone resorption (a process that can not occur on tissue culture plastic). Although earlier studies[@b38][@b39][@b40] reported that RANKL can induce downregulation of cell cycle progression genes during the late stages of osteoclast differentiation, these studies were limited to cells cultured on plastic. Our results indicate that signaling mediated by bone substrate and itgb3 plays a crucial role in the life cycle of the osteoclast by regulating the switch from proliferation to terminal differentiation and activation of bone resorption. It is interesting to note that the bone substrate mediated repression of expression of genes associated with cell cycle progression in developing osteoclasts is not seen in macrophages differentiated in the absence of RANKL. Macrophages, like osteoclasts, show a decrease in expression of cell cycle progression genes during extended culture, likely reflecting a transition to confluency. Importantly, however, unlike the bone substrate-mediated switch from osteoclast proliferation to activation, macrophage cell cycle progression is not further regulated by bone substrate.

In addition to the observed effect on regulation of cell cycle progression and cell division, bone substrate was also shown to significantly regulate the S-1-P pathway responsible for the biosynthesis, transport and signaling of S-1-P. Moreover, this pathway was independently regulated by RANKL signaling, bone substrate and itgb3 mediated attachment of osteoclasts to bone, indicating that multiple signals driving osteoclast differentiation converge upon this pathway. We observe tight coupling between induction of sphingosine kinase (to generate S-1-P) and the transporter Spns2 (to export S-1-P), suggesting that upregulation of the S-1-P pathway during osteoclastogenesis is coupled to increased production and autocrine/paracrine signaling by S-1-P. Immunohistochemical analysis on samples from RA patients confirmed that SphK1 is strongly expressed in bone resorbing inflammatory osteoclasts in humans. Importantly, we demonstrated SphK1 inhibitors blocked *in vitro* differentiation of mouse and human osteoclasts and expression of osteoclast associated genes. Consistent with the inhibition of TRAP-positive osteoclast formation and osteoclast gene expression, SphK1 inhibition also eliminated bone resorption following osteoclast differentiation on bone substrate, although further studies are needed to determine whether this is secondary to differentiation defects, or indicative of a direct involvement of SphK1 in osteoclast activation. Such studies will focus on the effects on osteoclast resorptive activity of inhibiting SphK1 following terminal differentiation on bone substrates. Taken together, these results suggest that the S-1-P pathway is a critical mediator of osteoclastogenesis that is up-regulated not only by RANKL signaling, but also during later stages of osteoclast differentiation by itgb3-mediated attachment to bone.

Sphingosine kinase and S-1-P signaling have previously been implicated in various aspects of osteoclast biology. Ishii et al[@b23][@b24][@b25] have demonstrated that interactions between S-1-P and the S-1-P receptor S1PR1 on osteoclast precursors mediated chemotaxis of these cells to bone surfaces from the bloodstream, and hence regulate bone homeostasis. S1PR1 expression is down-regulated during RANKL-induced differentiation of osteoclast precursors (a finding confirmed by our microarray data). However, as previously described by Pederson et al.[@b27] and validated in the present study, differentiating osteoclasts greatly amplify their ability to generate S-1-P and hence potentially recruit additional precursors to the sites of fusion and osteoclast activation, as well as regulating coupling to bone formation via interaction with S-1-P receptors on the surface of osteoblasts. Our findings that inhibition of SphK1 represses not only generation of multinucleated osteoclasts but also expression of multiple early and late osteoclast genes suggests that the role of S-1-P in osteoclastogenesis is not limited to recruitment of precursors to fusing osteoclasts. This is further supported by the observation that inhibition of SphK1 during early (pre-fusion) stages of osteoclastogenesis is sufficient to block differentiation. It has been reported that one of the SphK inhibitors used here (N′,N′-DMS) represses osteoclastogenesis in a SphK1-independent manner[@b41]; however, our observation that Compound 54, a SphK1-specific inhibitor, blocks osteoclast formation argues against this. However, the mechanism(s) by which SphK1 generated S-1-P inhibits osteoclastogenesis remain to be elucidated. In addition to signaling through cell surface S-1-P receptors, S-1-P can act intracellularly, raising the possibility of involvement of multiple possible paracrine and cell-autonomous mechanisms.

In addition to the above described roles of S-1-P signaling in RANKL-induced osteoclastogenesis, several lines of evidence point towards involvement of this pathway in the regulation of TNF signaling. SphK1 deficiency protects mice from TNF-induced arthritis[@b42]. Mechanistically, SphK1-generated S-1-P has been shown to act as a cofactor for TRAF2 downstream of TNF signaling required for signal transduction from TNFR1 to NF-kB[@b43]. Although TNF alone is insufficient to induce osteoclastogenesis under most conditions, it can potently synergize with low levels of RANKL to drive osteoclast generation[@b44], and therefore represents a major mediator of osteoclast mediated bone resorption in inflammatory disease. Thus, the S-1-P pathway may represent a particularly attractive candidate for therapeutic targeting of inflammatory osteoclasts.

Taken together, these studies have for the first time characterized at the molecular level the roles played by bone substrate in the differentiation and activation of osteoclasts. Bone regulates numerous signaling pathways, some but not all of which are dependent upon itgb3-mediated attachment to the substrate, including cell cycle progression and the generation, transport and signaling of S-1-P. Since authentic osteoclasts exist *in vivo* exclusively on bone, these findings are critical for a full understanding of osteoclast differentiation and identification of specific therapeutic targets within resorbing osteoclasts.

Methods
=======

Differentiation of mouse BMM-derived osteoclasts on different substrates
------------------------------------------------------------------------

Devitalized mouse calvarial bone discs were prepared as described[@b8]. M-CSF dependent BMM were generated from bone marrow cells from 4 individual 6 week old wild-type mice (C57Bl/6) as described[@b17]. Cells were then cultured at a density of 5 × 10^5^ per well in 24 well dishes (Corning Inc., Corning, NY) in the presence of 20 ng/ml mouse M-CSF (R&D Systems, Minneapolis, MN) or mouse M-CSF + RANKL (20 ng/ml each) (R&D Systems, Minneapolis, MN) on the devitalized bone discs, or on tissue culture plastic, or on synthetic HA (Osteologic discs, BD Bioscience, Franklin Lakes, NJ) for 1, 3 and 5 days. Following culture, RNA was extracted using Trizol, quantitated and assessed for purity, and subjected to microarray analysis. Cells in duplicate wells were fixed with cold 4% paraformaldehyde for 10 minutes for histological staining.

In a second experiment, M-CSF dependent BMM were generated from bone marrow cells from 3 wild-type mice (C57Bl/6) and 3 itgb3 deficient[@b12] mice as described above and cultured at a density of 5 × 10^5^ per well in 24 well dishes (Corning Inc., Corning, NY) in the presence of mouse M-CSF + RANKL (20 ng/ml each) (R&D Systems, Minneapolis, MN) on devitalized bone discs, or on tissue culture plastic, for 5 days, prior to RNA extraction and microarray analysis or fixation and staining.

TRAP and actin ring staining
----------------------------

Verification of pre-osteoclasts was confirmed by staining for tartrate resistant acid phosphatase (TRAP) and actin ring formation in wild-type and itgb3 deficient osteoclasts was visualized by rhodamine-phalloidin. TRAP staining was performed using the napthol-based method[@b45]. Briefly, cells were incubated with 0.05 mol/L Acetate buffer, pH 5.0, containing 0.27 mmol/L naphthol AS-MX phosphate (Sigma-Aldrich, St. Louis, MO), 1% vol/vol N,N-dimethylformamide, 1.6 mmol/L Fast Red LB salt and 50 mmol/L sodium tartrate at 37°C for 10 minutes.

Following TRAP staining, cells were permeabilized with 0.1% Triton X-100 in PBS for 3--5 mins. After washing with PBS, cells were incubated with rhodamine-conjugated phalloidin solution (Molecular Probes, Carlsbad, CA) diluted 1/200 in PBS containing 1% BSA for 1 hr. Actin rings were detected by fluorescence microscopy (Olympus BX-FLA, Osaka).

Microarray experiments and data analysis
----------------------------------------

One microgram total RNA was used to synthesize cRNA using the Affymetrix expression protocol (Expression Analysis Technical Manual; Affymetrix, Santa Clara, CA). Ten micrograms labeled and fragmented cRNA was hybridized to Affymetrix MOE430.2 chips (Affymetrix, Santa Clara, CA), and detection signal was calculated using MAS5 algorithm in GCOS (Expression Analysis Technical Manual; Affymetrix) and sample normalization was performed using global scaling.

Fold change differences and p-values were calculated using ANOVA, and genes were considered differentially regulated if they had a fold change of ±2 between groups, and if the false-discovery-rate corrected p-value was \<0.05. Hierarchical clustering was performed with signal values on differentially-regulated genes, normalized to between 0 and 1 for each gene, and then clustered via Ward\'s method.

Pathway analysis was conducted by the Gene Set Enrichment Analysis (GSEA) method[@b46], using the detection signals as input data, and pathway sets from Biocarta. Resulting pathways were ranked by FDR q value. Additional functional analysis was conducted on subsets of the genes using Ingenuity IPA.

Immunohistochemistry
--------------------

Formalin-fixed, paraffin embedded sections from patients with inflammatory bone erosions (RA, peri-implant osteolysis) were sectioned and detected with 1:100 (5 μg/ml) rabbit anti-human SphK1 antibody (ab16491, abcam, Cambridge, MA) or isotype control diluted in PBS. Antigen retrieval was for 7 minutes in 10 mM EDTA pH.7.6 in a scientific microwave, followed by inhibition of endogenous hydrogen peroxidase with 3% H~2~O~2~ in water for 20 minutes at room temperature and blocking with: 1.5% normal goat serum (Vector Laboratories, Burlingame, CA) + 5% FCS for 30 min at room temperature. Secondary antibody and detection steps were performed using Vector Laboratories kits (Vector Laboratories, Burlingame, CA) following the manufacturers recommendations.

Sphingosine kinase inhibitors
-----------------------------

N, N-Dimethylsphingosine \[2S-(dimethylamino)-4E-octadecene-1,3R-diol; CAS Registry No: 119567-63-4\] was purchased from Cayman Chemical (Ann Arbor, MI, supplied in DMSO). Compound 54 was prepared as described[@b30] and was solvated in dimethyl sulfoxide (DMSO). Inhibitors were submitted to Invitrogen/Life Technologies SelectScreen kinase profiling service for assessing selectivity against lipid kinases (lipid kinase panel) and/or protein kinases (kinome sampler panel, 50 kinases) at a concentration of 10 μmol/L. Enhanced selectivity for SphK1 versus SphK2 was confirmed for Compound 54 (100% SphK1 inhibition, with minimal inhibition of SphK2, 18% inhibition). Of protein kinases, N′,N′-DMS led to 43% inhibition of TRKA and Compound 54 led to 31% inhibition of FLT3. Neither compound led to substantial inhibition of any other lipid and/or protein kinase tested (\<27% inhibition; data not shown).

*In vitro* osteoclastogenesis assays in the presence of SphK1 inhibitors
------------------------------------------------------------------------

Bone marrow macrophages (BMM) from *C57BL6* mice were isolated by culture of bone marrow cells for three days on petri dishes in α-MEM medium supplemented with 10% FBS, 1% penicillin-streptomycin (Invitrogen, Carlsbad, CA) and 10% (equivalent to 140 ng/ml M-CSF) conditioned medium from the M-CSF overproducing cell line CMG[@b47]. Adherent cells were collected by trypsinization and then cultured in multi-well tissue culture plastic dishes. For osteoclastogenesis, cells were cultured at 5 × 10^4^ cells/ml in the same medium with GST-RANKL added to 0--50 ng/ml, in 96-well dishes (200 μl per well) or 24-well dishes (1 ml per well). Where required, slices of bovine cortical bone were inserted into the wells prior to addition of cells. Medium was changed after three days. Sphk inhibitors were added at various doses for either the first 3 days, the last 2 days, or for all five days. DMSO was added at equivalent levels to control cultures. Osteoclastogenesis was assessed on day 5 by TRAP staining (Sigma-Aldrich, St. Louis, MO, kit 386A) followed by counting of TRAP-positive, multinuclear (3 + nuclei) cells. Bone resorption was assessed by removal of cells from bone slices with 2 M NaOH, and incubation for 30 minutes with 20 μg/ml peroxidase-conjugated wheat germ agglutinin (Sigma-Aldrich, St. Louis, MO) followed by 30 minutes with 3,3′-diaminobenzidine substrate solution (Vector Laboratories, Burlingame, CA). For generation of human osteoclasts, CD14-positive monocytes were prepared from PBMCs derived from de-identified normal human donors as described previously[@b48]. Cells were then cultured at a cell density of 1--2 × 10^6^ cells per milliliter in α-MEM medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (VWR, West Chester, PA) and 1% antibiotic/antimycotic (Invitrogen, Carlsbad, CA) in the presence or absence of 25 ng/ml human M-CSF (Peprotech, Rocky Hill, NJ) in 12-well tissue culture plates (1 ml per well). For osteoclastogenesis, cells were cultured at 3 × 10^5^ cells/ml in the same medium with GST-RANKL added to 0--40 ng/ml, in 96-well dishes (200 μl per well) or 24-well dishes (1 ml per well) in the presence or absence of inhibitors. Medium was changed every three days. Osteoclastogenesis was assessed on day 7--9 by TRAP staining, as described above.

RNA extraction and qPCR
-----------------------

RNA was extracted (RNeasy Mini kit, QIAGEN Inc., Valencia, CA) and assessed for concentration and purity by optical density measurement. 500 ng aliquots of total cellular RNA were reverse transcribed using oligo-dT primers and MMLV reverse transcriptase (First Strand cDNA Synthesis Kit, Fermentas) as recommended by the manufacturer. Real time quantitative PCR (qPCR) was carried out in duplicate using the iCycler iQ thermal cycler detection system (Bio-Rad Laboratories Inc., Hercules, CA). Reactions included iQ™ SYBR® Green Supermix reagent (Bio-Rad Laboratories Inc., Hercules, CA), 10 ng cDNA, and forward and reverse primers each at a concentration of 250 nM in a total volume of 25 μl. mRNA amounts were normalized relative to the house-keeping genes HPRT or GAPDH, and quantified using the ΔΔCt method[@b49]. Generation of only the correct amplification products was confirmed using melting point curve analysis of the products. The sequences of the oligonucleotide primers used were:

Mouse AnxA8: GGCTATCTGGAGCGGATTCTG/CGGTTCCCATAATCTTCTCACC

Mouse UCHL1: AGGGACAGGAAGTTAGCCCTA/AGCTTCTCCGTTTCAGACAGA

Mouse FKBP9: AGCTTCTCCGTTTCAGACAGA/TCTGGCCGTCGAGGAAAGT

Mouse SphK1: GATGCATGAGGTGGTGAATG/GCTACACAGGGGTTTCTGGA

Mouse Spns2: GGCATCTTCTTCTGGTCTGC/ATGATGGTGGGTGCCTATGGT

Mouse Cathepsin K: GAGGCGGCTATATGACCACTG/CATACAACTTTCATCCTGGCCC

Mouse HPRT: AGCTACTGTAATGATCAGTCAACG/AGAGGTCCTTTTCACCAGCA
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![Bone substrate regulates gene expression in differentiating murine osteoclasts.\
(a) Phalloidin stain showing distinctive actin morphology of wild type BMM-derived osteoclasts differentiated on bone. (b) Phalloidin stain showing distinctive actin morphology of wild type BMM-derived osteoclasts differentiated on plastic. (c) Hierarchical clustering heat map of mouse BMM-derived osteoclast expression profiles regulated by RANKL, stage of differentiation and culture substrate. (d) Total numbers of RANKL-induced genes that are further regulated, or unaffected, by bone substrate. (e) Venn diagram of the overlap between genes regulated \>2× by bone on days 1, 3 and 5.](srep07595-f1){#f1}

![Itgb3 signaling mediates the effects of bone substrate on osteoclastogenesis.\
(a) Detailed microarray analysis of itgb3 expression in cells cultured for 1, 3 and 5 days on plastic or calvaria (bone), in the presence (+RL) or absence (−RL) of RANKL. (b) Phalloidin stain showing distinctive actin morphology of itgb3 deficient BMM-derived osteoclasts differentiated on bone. (c) Hierarchical clustering heat map of mouse BMM-derived bone induced osteoclast expression profiles regulated by itgb3.](srep07595-f2){#f2}

![Regulation of cell cycle progression and proliferation by bone substrate and itgb3.\
(a) GSEA analysis showing modulation of the cell cycle progression pathway by both bone and itgb3. (b) Detailed microarray analysis of cdc7 and Cyclin B1 probe sets in cells cultured for 1, 3 and 5 days on plastic or calvaria (bone), in the presence (+RL) or absence (−RL) of RANKL.](srep07595-f3){#f3}

![Regulation of the S-1-P pathway by RANKL, bone and itgb3.\
(a) GSEA analysis showing that RANKL, bone and itgb3 each independently modulates this pathway. (b) Detailed microarray analysis of SphK1 and Spns2 probe sets in cells cultured for 1, 3 and 5 days on plastic or calvaria (bone), in the presence (+RL) or absence (−RL) of RANKL. (c) Pathway analysis showing S-1-P pathway components that are co-coordinately regulated by RANKL, itgb3 and bone substrate during osteoclastogenesis. (d) Immunohistochemistry analysis showing SphK1 expression in osteoclasts on the bone surface in sites of rheumatoid arthritis bone erosions.](srep07595-f4){#f4}

![Inhibition of SphK1 represses RANKL-induced murine and human osteoclastogenesis on plastic and bone.\
(a) Inhibition of RANKL-induced murine osteoclast formation by Sphk1 inhibitors (N′,N′-DMS and Compound 54) as assessed by quantitation of TRAP-positive multinucleated cells (n = 3, ~\*~ = p \< 0.05 compared to DMSO control). (b) Pit formation assay showing that the inhibitors (at 2.5 uM) inhibit osteoclast mediated bone resorption. (c) Effects of SphK1 inhibitors on RANKL-induced expression of Cathepsin K as assessed by quantitative PCR (n = 3, ~\*~ = p \< 0.05 compared to DMSO control). (d) Inhibition of RANKL-induced human monocyte-derived osteoclast formation by Sphk1 inhibitors (N′,N′-DMS and Compound 54) as assessed by quantitation of TRAP-positive multinucleated cells (representative experiment of three).](srep07595-f5){#f5}

###### Comparison of microarray and quantitative RT-PCR expression analysis for selected genes. Wild-type (WT) and integrin beta 3 deficient (Itgb3KO) cells were cultured on plastic or bone substrate with M-CSF and RANKL for 5 days. For each analysis, expression in wild-type cells (WT) cultured on plastic is set to a value of 1.00, and relative values and standard deviations calculated. Primer sequences are given in the *Methods* Section

                              Microarray Analysis      Quantitative RT-PCR                                                                            
  ----------------------- ------------------------ ------------------------ -------------- -------------- ------------- --------------- ------------- ---------------
  AnxA8 (1425789_s\_at)         1.00 (0.60)              12.86 (0.80)        0.46 (0.28)    13.33 (1.98)   1.00 (.034)   66.47 (16.98)   1.34 (0.04)   73.96 (19.40)
  AnxA8 (1417732_at)            1.00 (0.33)              14.40 (0.80)        0.64 (0.23)    15.88 (1.87)                                                      
  UCHL1 (1448260_at)            1.00 (0.04)              1.69 (0.06)         0.02 (0.005)   0.04 (0.01)    1.00 (0.13)    2.09 (0.34)    0.02 (0.01)    0.06 (0.03)
  FKBP9 (1423677_at)            1.00 (0.08)              1.58 (0.12)         0.19 (0.04)    0.16 (0.04)    1.00 (0.41)    2.91 (1.23)    0.20 (0.09)    0.21 (0.19)
  FKBP9 (1437687_x\_at)         1.00 (0.02)              1.49 (0.03)         0.15 (0.002)   0.13 (0.01)                                                       
  SphK1 (1451596_a\_at)         1.00 (0.03)              1.52 (0.16)         0.60 (0.06)    0.80 (0.08)    1.00 (0.66)    1.54 (0.48)    0.57 (0.15)    0.83 (0.51)
  Spns2 (1451601_a\_at)         1.00 (0.09)              1.69 (0.07)         1.62 (0.08)    1.48 (0.21)    1.00 (0.26)    2.39 (0.41)    1.51 (0.70)    1.76 (0.39)

###### Pathway and functional analysis of gene sets regulated by bone substrate

  Category                             p-Value                                                                                                                                                                                                                                                                                                                                                         Molecules
  ----------------------------------- ---------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cellular Function and Maintenance    4.65E-06                                                                                                                                                                          ACAP1, ATG4C, ATM, AXL, BNIP3, CA9, CADM1, CADPS, CCL22, CLEC6A, COL5A3, CRYAB, CXCL3, DCLRE1C, DDIT4, EGR1, ERO1L, FAS, FCGR2B, FPR2, FXYD2, GATM, GHR, GNA13, ICA1, IL7R, KCNJ10, KIF5B, LAMA3, MAP1LC3A, MBP, MED1, MSR1, MT1H, MTM1, MYSM1, NDRG1, NMB, NOS3, NPY, NUCB2, NUPR1, Rps6/Rps6-ps4, SESN2, SLC12A2, SLC2A1, SLC37A4, SLC8A1, STAP2, TRIB3, WWP2, ZEB1
  Cell Death and Survival              1.25E-05                 ABCA3, AIM2, ALDH2, AMACR, AQP9, ARG1, ATM, AXL, BMP2, BNIP3, BUB1, CA9, CADM1, CADPS, CASP4, CCL27, CD2AP, CD300LD, Cd59a, CHST11, COL5A3, CRYAB, CTH, CXCL3, DCLRE1C, DDIT4, DSG2, DSP, EGR1, EHD3, EYA1, FAM162A, FAS, FCGR2B, FHL2, FOXK2, FSTL1, FUBP1, G2E3, GHR, GLO1, GNA13, GNAI1, GRIA3, H60a, HK2, HYOU1, IBSP, Ifi202b, IL7R, ITCH, ITGB3, JAG1, KCNJ10, KLRD1, LAMA3, LATS1, MAP1LC3A, MBD4, MBP, MED1, MPO, MSI2, MSR1, MT1H, MTM1, NDRG1, NLE1, NOS3, NPY, NSF, NUPR1, PAFAH1B2, POU2AF1, PPP2R1B, Pvr, RAI14, Rps6/Rps6-ps4, SESN2, SIK1, SLC12A2, SLC2A1, SLC8A1, STAP2, SUB1, TIA1, TIMP2, TNFRSF14, TNFRSF9, TRIB3, UCHL1, URI1, VAMP3, WASF1, WWP2, XAF1, ZEB1, ZFR
  Cellular Growth and Proliferation    1.81E-05   ADAMTS4, AIM2, AK4, AMACR, APOBEC1, AQP9, ARF1, ARG1, ARHGAP5, ARHGDIG, ATM, AXL, BMP2, BNIP3, BPNT1, BUB1, CA9, CACUL1, CADM1, CCDC19, CCL27, CD2AP, Cd59a, CD84, CHST11, CREB3, CRYAB, CTH, CXCL3, DCLRE1C, DFNA5, DSG2, DSP, DUSP8, EGR1, ELOVL7, EPS8, ERO1L, EYA1, FAS, FCGR2B, FHL2, FPR2, FSCN1, FXYD2, GFER, GHR, GNA13, GNAI1, GRIA3, H60a, HAO1, HK2, IBSP, Ifi202b, Ifi204, IGF2BP3, IL7R, ITCH, ITGB3, JAG1, KLRD1, LAMA3, LATS1, MAPRE1, MBP, MED1, MSI2, MSR1, MT1H, NDRG1, NMB, NOS3, NPY, NUCB2, NUPR1, P4HA2, PLS3, POU2AF1, PPP2R1B, PTX3, Pvr, QPCT, RHOU, SIK1, SLC12A2, SLC2A1, SLC8A1, STAP2, TIMP2, TLE6, Tmsb4x, TNFRSF14, TNFRSF9, TPM2, TRIB3, UCHL1, URI1, VLDLR, VPS39, WLS, WWP2, ZEB1
  Cellular Movement                    2.21E-05                                                                                                                                AQP9, ARF1, ARG1, ARHGAP5, ATM, AXL, BMP2, C1GALT1, CA9, CADM1, CCL22, CCL27, Cd59a, CD99L2, CREB3, CRYAB, CXCL3, EGR1, ELK3, EPS8, FAS, FCGR2B, FHL2, FPR2, FSCN1, FSTL1, GNA13, GNAI1, GRIA3, ITCH, ITGB3, JAG1, LAMA3, MAPRE1, MBP, MED1, MPO, MSR1, NDRG1, NOS3, NPY, NUCB2, P4HA2, POU2AF1, PTX3, Pvr, QPCT, RAP2B, RHOU, ROPN1L, SEMA3C, SLC12A2, SLC2A1, SLC37A4, SLC8A1, STAP2, TIMP2, TLE6, Tmsb4x, TNFRSF14, TNFRSF9, USP14, VLDLR, WASF1, ZEB1
  Amino Acid Metabolism                2.47E-05                                                                                                                                                                                                                                                                                                                                                 GATM, NAGS, NOS3, QPCT
